Perioperative chemotherapy versus adjuvant chemotherapy treatment for resectable locally advanced gastric cancer: a retrospective cohort study

Perioperative chemotherapy versus adjuvant chemotherapy treatment for resectable locally advanced gastric cancer: a retrospective cohort study

Abstract Background Neoadjuvant chemotherapy (NAC) is increasingly used in locally advanced gastric cancer (LAGC), but the clinical safety and efficacy are still controversial. This study aims to compare perioperative chemotherapy (PEC) with adjuvant chemotherapy (AC) for resectable LAGC. Methods Pa...

Full description

Bibliographic Details
Main Authors:	Pengfei Su, Lin Jiang, Yingjing Zhang, Tian Yu, Hongyun Huang, Moxi Chen, Can Cao, Weiming Kang, Yuqin Liu, Jianchun Yu
Format:	Article
Language:	English
Published:	BMC 2023-10-01
Series:	European Journal of Medical Research
Subjects:	Gastric cancer Perioperative chemotherapy Neoadjuvant chemotherapy Adjuvant chemotherapy Survival benefit
Online Access:	https://doi.org/10.1186/s40001-023-01400-3

Similar Items

The significance of time interval between perioperative SOX/XELOX chemotherapy and clinical decision model in gastric cancer
by: Jun-Bing Chen, et al.
Published: (2022-12-01)

Updated Adjuvant Chemotherapy for Gastric Cancer
by: Toshizo Takayama, et al.
Published: (2023-10-01)

Comparison of the effects of perioperative and adjuvant chemotherapy on outcomes of operable gastric cancer: a retrospective cohort experience from a tertiary cancer center
by: Jamshed Ali, et al.
Published: (2023-03-01)

Intraperitoneal Chemotherapy as Adjuvant or Perioperative Chemotherapy for Patients with Type 4 Scirrhous Gastric Cancer: PHOENIX-GC2 Trial
by: Hironori Ishigami, et al.
Published: (2021-11-01)

Perioperative versus adjuvant S-1 plus oxaliplatin chemotherapy for stage II/III resectable gastric cancer (RESONANCE): a randomized, open-label, phase 3 trial
by: Xinxin Wang, et al.
Published: (2024-04-01)

Impact of Signet-Ring Cell Histology in the Management of Patients with Non-Metastatic Gastric Cancer: Results from a Retrospective Multicenter Analysis Comparing FLOT Perioperative Chemotherapy vs. Surgery Followed by Adjuvant Chemotherapy
by: Riccardo Giampieri, et al.
Published: (2023-06-01)

Does postoperative chemotherapy improve overall survival of patients with ypT1-2N0 cancer?
by: Pengfei Su, et al.
Published: (2022-12-01)

Perioperative Treatment in Resectable Gastric Cancer: Current Perspectives and Future Directions
by: Angelica Petrillo, et al.
Published: (2019-03-01)

Neoadjuvant chemotherapy for locally advanced gastric cancer in Japan: Consensus meeting at the 77th general meeting of the Japanese Society of Gastroenterological Surgery
by: Masanori Tokunaga, et al.
Published: (2023-11-01)

Neoadjuvant Chemotherapy and Adjuvant Chemoradiation Therapy in the Treatment of Resected Gastric Adenocarcinoma: A Case Series
by: Christina Hadzitheodorou, et al.
Published: (2017-04-01)

Feasibility and Safety of Perioperative Chemotherapy With Fluorouracil Plus Leucovorin, Oxaliplatin, and Docetaxel for Locally Advanced Gastric Cancer Patients in China
by: Birendra Kumar Sah, et al.
Published: (2021-01-01)

Perioperative chemotherapy for gastric cancer: the current state
by: V K Lyadov, et al.
Published: (2018-06-01)

Neoadjuvant or adjuvant chemotherapy: what is the best treatment of muscle invasive bladder cancer?
by: Nabil Ismaili, et al.
Published: (2011-09-01)

Safety and preliminary results of perioperative chemotherapy and hyperthermic intraperitoneal chemotherapy (HIPEC) for high-risk gastric cancer patients
by: Costa Wilson L, et al.
Published: (2012-09-01)

Localized stomach cancer: Perioperative or postoperative approach? A meta‐analysis of phase III studies
by: Wala Ben Kridis, et al.
Published: (2022-04-01)

Impact of Postoperative Chemotherapy in Patients with Gastric/Gastroesophageal Adenocarcinoma Treated with Perioperative Chemotherapy
by: Alexej Ballhausen, et al.
Published: (2022-03-01)

Clinicopathological factors affecting the effect of neoadjuvant chemotherapy in patients with gastric cancer
by: Lin Jiang, et al.
Published: (2021-02-01)

Editorial: Optimal perioperative management of urothelial carcinoma
by: Ariane Holzman, et al.
Published: (2023-05-01)

Feasibility study of adjuvant chemotherapy with S-1 after curative esophagectomy following neoadjuvant chemotherapy for esophageal cancer
by: Noriyuki Hirahara, et al.
Published: (2022-06-01)

Perioperative Chemotherapy for Liver Metastasis of Colorectal Cancer
by: Gloria Chan, et al.
Published: (2020-11-01)

High-risk bladder cancer: improving outcomes with perioperative chemotherapy
by: Daniel Y.C. Heng, et al.
Published: (2011-12-01)

High-risk bladder cancer: improving outcomes with perioperative chemotherapy
by: Daniel Y.C. Heng, et al.
Published: (2011-12-01)

Prognostic significance of adjuvant chemotherapy in patients with gastric neuroendocrine carcinoma
by: ZHANG Rihong, GUO Yu, LIANG Yun, CHEN Luohai, CHEN Jie, WANG Wei
Published: (2022-09-01)

Perioperative Chemotherapy with FLOT Scheme in Resectable Gastric Adenocarcinoma: A Preliminary Correlation between TRG and Radiomics
by: Giovanni Maria Garbarino, et al.
Published: (2021-10-01)

Is adjuvant chemotherapy necessary for early gastric cancer?
by: Yu Mei, et al.
Published: (2022-04-01)

Gastric cancer: histological response of tumor and metastatic lymph nodes for perioperative chemotherapy
by: Telma Fonseca, et al.
Published: (2022-01-01)

Impact of Adjuvant Chemotherapy on Survival of Patients with Advanced Residual Disease at Radical Cystectomy following Neoadjuvant Chemotherapy: Systematic Review and Meta-Analysis
by: Wojciech Krajewski, et al.
Published: (2021-02-01)

Clinical Outcomes of Neoadjuvant Versus Adjuvant Chemotherapy on Muscle-invasive Bladder Cancer
by: DENG Kangli, et al.
Published: (2019-04-01)

Body Mass Index and Prognosis of Patients With Stage II/III Gastric Cancer After Curative Gastrectomy: Completion of Perioperative Adjuvant Chemotherapy May Be a Confounding Factor
by: Wei Peng, et al.
Published: (2022-06-01)

Adjuvant chemotherapy for gastric cancer
by: I. P. Kolesnyk, et al.
Published: (2015-12-01)

Comparison of responses to neoadjuvant and adjuvant chemotherapies in muscle-invasive bladder cancer
by: Serhat Sekmek, et al.
Published: (2023-11-01)

Docetaxel, Cisplatin, and 5‐Fluorouracil as perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma
by: Frédéric Fiteni, et al.
Published: (2016-11-01)

Lobe‐specific analysis of perioperative chemotherapy for non‐small cell lung cancer patients
by: Xi Lei, et al.
Published: (2023-08-01)

Association between Pre-Treatment Biological Indicators and Compliance to Neoadjuvant/Perioperative Chemotherapy in Operable Gastric Cancer
by: Manlio Monti, et al.
Published: (2023-08-01)

Pattern of Recurrence and Patient Survival after Perioperative Chemotherapy with 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) for Locally Advanced Esophagogastric Adenocarcinoma in Patients Treated Outside Clinical Trials
by: Torben Glatz, et al.
Published: (2020-08-01)

Chemotherapy Regimens for Non-Metastatic Conventional Appendicular Osteosarcoma: A Literature Review Based on the Outcomes
by: Joaquim Soares do Brito, et al.
Published: (2023-06-01)

Patients achieved pCR during neoadjuvant chemotherapy had better outcome than adjuvant chemotherapy setting in breast cancer: A comparative study
by: Jida Chen, et al.
Published: (2023-01-01)

Is there any advantage to combined trastuzumab and chemotherapy in perioperative setting her 2neu positive localized gastric adenocarcinoma?
by: Albouzidi Abderrahmane, et al.
Published: (2011-09-01)

Optimizing the Choice for Adjuvant Chemotherapy in Gastric Cancer
by: Antonino Grassadonia, et al.
Published: (2022-09-01)

Elderly patients with stage II gastric cancer do not benefit from adjuvant chemotherapy
by: Jianping Guo, et al.
Published: (2023-10-01)